A JAMA Oncology viewpoint argues that the COVID-19 pandemic presents a prime opportunity to make clinical trial design and execution more efficient.
The cancer research community needs to filter out wasteful clinical trials and encourage research that challenges unproven practices that consume resources, three Canadian researchers argue in an opinion piece published today in JAMA Oncology about cancer research after COVID-19.
The viewpoint, titled “The Day After COVID-19 — Time to Rethink Oncology Clinical Research,” argues for a more selective approach to research that will is more likely to yield meaningful results while also husbanding resources.
Daniel Araujo, M.D., Geoffrey A. Watson, M.D., and Lillian L. Siu, M.D., all of the Princess Margaret Cancer Centre in Toronto, also discuss the possibility of a greater reliance on telemedicine, virtual tumor boards, and centralized artificial intelligence facilitating “the search for suitable clinical trials.”
“Clinical research must be leaner and more efficient,” they write. “It is time to incorporate new technologies, revisit old practices and move forward toward better outcomes for our patients.:
Here are some of the points they made: